Sr. Director, U.S. Asset Lead - Oncology (Lung & GU Tumors)

Sr. Director, U.S. Asset Lead - Oncology (Lung & GU Tumors)

Location: Philadelphia, PA

The Sr. Director, U.S. Asset Lead is the primary U.S. commercial representative for the asset across lung and genitourinary (GU) tumors. This leader embeds U.S. market perspective into clinical development, regulatory and access strategy, and launch planning to maximize commercial value from development through lifecycle management. The role partners with global and U.S. functions to ensure development decisions support U.S. commercialization.

Key responsibilities:

U.S. as strategy & leadership

• Act as U.S. commercial lead ensuring U.S. priorities are reflected in global asset decisions.
• Define U.S. Target Product Profile, positioning, differentiation and value proposition versus competitors.
• Translate U.S. market insights into actionable guidance for global teams.

Clinical development & indication strategy

• Provide commercial input on indication prioritization, endpoints, comparator strategy, and trial design.
• Identify label-optimizing opportunities and evidence needs to support U.S. access and adoption.

Market intelligence & competitive strategy

• Support U.S. market landscape analyses: epidemiology, treatment pathways, competitive pipelines and emerging modalities.
• Partner with Business Insights/Analytics to surface signals that drive strategic shifts.

Forecasting & business case

• Collaborate on U.S. revenue forecasting, scenario planning and pricing/market uptake assumptions.
• Inform investment, launch sequencing and lifecycle decisions with commercial assessments.

Launch readiness & commercialization

• Inform U.S. launch planning: customer segmentation, messaging, access/pricing strategy and go-to-market model.
• Support in the cross functional commercialization planning: Sales, Marketing, Market Access and Medical Affairs for coordinated launch execution.

Cross-functional & external engagement

• Integrate with Global Asset Team, Medical, Regulatory, Market Access, and Forecasting.
• Engage KOLs, advocacy groups and present at major oncology congresses to inform strategy and market shaping.

Leadership competencies

• Strategic thinker with strong commercial acumen
• Data-driven decision maker
• Ability to influence without formal authority and drive cross-functional alignment
• Balances near-term development priorities with long-term asset value
• Impact
• This role ensures the product is developed and positioned to achieve maximum clinical adoption and commercial success in the U.S. market by embedding U.S. evidence, access and commercialization needs into global development and launch decisions.

Why You?

Basic Qualifications

• Bachelor’s degree in business, life sciences, healthcare or related field; advanced degree preferred.
• 10+ years in biopharma with substantial oncology commercial experience.
• Demonstrated experience supporting late-stage clinical development, launch planning, and/or commercialization of oncology assets
• Experience collaborating with cross‑functional stakeholders across Commercial, Medical, Regulatory, Market Access, and Forecasting in matrixed environments
• Proven success influencing global, matrixed teams.

Preferred Qualifications

• Advanced degree (MBA, PhD, PharmD, MD, or equivalent)
• Direct commercial experience in lung cancer and/or genitourinary (GU) tumor indications
• Experience serving as an asset lead or primary commercial representative on a global asset team
• Hands-on involvement in U.S. launch execution, including positioning, pricing, access strategy, and go‑to‑market planning
• Deep familiarity with U.S. payer evidence requirements, value frameworks, and access strategy for oncology therapies

#LI-GSK

Please visit  GSK US Benefits Summary to learn more about the comprehensive benefits program GSK offers US employees.

Why GSK?

Uniting science, technology and talent to get ahead of disease together.

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. We get ahead of diseas